Generic User Fees Must Be Considered Due To Ballooning ANDAs – FDA’s Galson

The "exponential" growth of ANDA submissions necessitates an examination of user fees for generic applications, Center for Drug Evaluation & Research Director Steven Galson told the Generic Pharmaceutical Association's Fall Technical Conference Oct. 24